Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. (Nasdaq: NRIX) is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines in oncology, autoimmune disease and inflammatory conditions. The NRIX news feed on Stock Titan aggregates company announcements, clinical updates and regulatory disclosures so readers can follow how its pipeline and collaborations evolve over time.
News about Nurix frequently centers on clinical trial results and milestones for its lead programs. Recent releases describe new and updated data from Phase 1a/1b studies of the BTK degrader bexobrutideg (NX-5948) in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, including objective response rates, durability of responses and safety findings. Additional updates cover translational and clinical data for NX-1607, an oral CBL-B inhibitor for solid tumors, highlighting immune activation, tumor microenvironment remodeling and disease control in heavily pretreated patients.
Investors and clinicians can also use the NRIX news page to track corporate and regulatory events such as the initiation of the pivotal DAYBreak CLL-201 Phase 2 study, plans for a confirmatory Phase 3 trial, expansion of bexobrutideg into autoimmune and inflammatory indications, and participation in major medical and investor conferences including the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer (SITC) and the J.P. Morgan Healthcare Conference.
Nurix’s news flow further includes announcements on strategic collaborations and governance, such as progress in partnered STAT6 and IRAK4 degrader programs with Sanofi and Gilead, and board appointments that add drug development and commercialization experience. Bookmark this page to access a consolidated view of NRIX press releases and related coverage as the company advances its targeted protein degradation pipeline.
Nurix Therapeutics (NRIX) reported Q3 fiscal 2024 financial results and provided a corporate update. Key highlights include:
1. Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia and other B-cell malignancies
2. Reinitiated enrollment for NX-2127 in a Phase 1a/b oncology trial
3. Presented preclinical data on Degrader-Antibody Conjugates (DACs)
4. Cash and marketable securities of $457.5 million
Financial results: Collaboration revenue was $12.6 million, down from $18.5 million in Q3 2023. R&D expenses increased to $55.5 million from $47.9 million. Net loss was $49.0 million or ($0.67) per share.
The company anticipates clinical data readouts in Q4 2024 and initiation of pivotal studies for NX-5948 in 2025.
Nurix Therapeutics (Nasdaq: NRIX) announced upcoming presentations of preclinical data at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, held November 14-19, 2024, in Washington, D.C. The presentations will focus on two of Nurix's drug candidates:
1. NX-5948: A BTK degrader in Phase 1b development for B-cell malignancies and IND-enabling studies for autoimmune diseases. The poster will showcase its efficacy in suppressing BCR, TLR, and FcR signaling in immune cells and its performance in preclinical models of arthritis and other inflammatory diseases.
2. GS-6791/NX-0479: An IRAK4 degrader developed in collaboration with Gilead Sciences, currently in IND-enabling studies. The presentation will demonstrate its ability to inhibit TLR and IL-1R-driven inflammatory signaling and its effects in a preclinical arthritis model.
Nurix Therapeutics (Nasdaq: NRIX) announced three oral presentations at the 22nd Annual Discovery on Target conference in Boston, MA, from September 30 to October 3, 2024. The presentations highlight Nurix's DELigase platform capabilities in addressing difficult-to-drug target classes like E3 ligases and transcription factors. The company will present on:
1. A small molecule inhibitor of CBL-B for enhanced T-cell function
2. The chemical space of bi-functional degraders targeting the CNS, including their clinical stage BTK degrader NX-5948
3. Screening DNA binding proteins with DNA Encoded Libraries, focusing on transcription factors
The presentation slides will be available on Nurix's website from October 1, 2024.
Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical company, has announced its participation in the upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit in Boston from September 9-10, 2024. Dr. Gwenn M. Hansen, the company's chief scientific officer, will present an update on Nurix's Degrader-Antibody Conjugate (DAC) platform on Tuesday, September 10, from 9:05 to 9:25 a.m. ET.
The presentation, titled 'Targeted Protein Degraders As Next Generation Antibody Payloads', will showcase Nurix's innovative approach to developing targeted protein modulation drugs for cancer and inflammatory diseases. Interested parties can access the presentation slides from September 9, 2024, through the Investors section of the Nurix website under Events and Presentations.
Nurix Therapeutics (Nasdaq: NRIX), a clinical stage biopharmaceutical company focusing on targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in three upcoming investor conferences in September 2024:
1. 2024 Wells Fargo Healthcare Conference in Boston, MA (September 5)
2. H.C. Wainwright 26th Annual Global Investment Conference in New York City (September 9)
3. Baird 2024 Global Healthcare Conference in New York City (September 10)
Key executives, including CEO Arthur T. Sands, CFO Hans van Houte, and CBO Jason Kantor, will participate in fireside chats and presentations. Most events will be webcast live and accessible through the Investors section of Nurix's website, with recordings available for 30 days after each event.
Nurix Therapeutics (Nasdaq: NRIX) reported its Q2 fiscal 2024 results, highlighting significant advancements. The company showcased positive clinical data for NX-5948 at the European Hematology Association Congress, demonstrating a 69.2% objective response rate in heavily pretreated CLL patients.
Financially, Nurix strengthened its cash position to $452.5 million, largely from a $188.7 million public offering. Key leadership appointments include Dr. Paula G. O’Connor as CMO and Dr. Pasit Phiasivongsa as CTO.
Q2 collaboration revenue grew to $12.1 million from $10.7 million YoY, driven by a milestone with Pfizer. However, R&D expenses increased to $48.9 million, contributing to a net loss of $44.5 million, or ($0.71) per share.
Nurix plans to advance NX-5948 into pivotal trials in 2025, alongside other pipeline developments including NX-2127 and NX-1607.
On July 8, 2024, Nurix Therapeutics (Nasdaq: NRIX), a clinical-stage biopharmaceutical firm focused on developing targeted protein modulation drugs for cancer and inflammatory diseases, announced its participation in the UBS Virtual Targeted Protein Degradation (TPD) Day. Dr. Arthur T. Sands, Nurix's President and CEO, will engage in a fireside chat at 2:30 p.m. ET on July 15, 2024. The discussion will be webcast live and accessible through the Investors section of Nurix's website, under Events and Presentations, and the archived version will remain available for 30 days post-event.
Nurix Therapeutics released positive results for NX-5948 during the EHA 2024 congress. The drug, targeting relapsed/refractory CLL, showed a 69.2% objective response rate in heavily pretreated patients, including those with BTK inhibitor resistance. Responses were rapid and deepened with prolonged treatment. Adverse events were manageable, with common side effects being purpura, thrombocytopenia, and neutropenia. Based on these results, Nurix plans pivotal trials in 2025. A webcast discussing these findings will be held on June 16, 2024, at 9:00 a.m. ET.
Nurix Therapeutics (Nasdaq: NRIX) will host a webcast and conference call on June 16, 2024, at 9:00 a.m. ET to discuss data from its ongoing Phase 1 clinical trial of NX-5948. This presentation will occur in an oral session at the European Hematology Association Congress in Madrid, Spain. The Phase 1a/b study of NX-5948 focuses on heavily pretreated patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. Key points include data on patients with BTK inhibitor resistance mutations and CNS involvement. The oral presentation, titled "Latest results from an ongoing first-in-human Phase 1a/b study of NX-5948," will be presented by Dr. Kim Linton on June 16, 2024, from 11:30 a.m. to 12:45 p.m. CEST.
Nurix Therapeutics (Nasdaq: NRIX) announced that its CEO, Dr. Arthur T. Sands, will present a corporate update at the Jefferies Global Healthcare Conference. This presentation is scheduled for June 5, 2024, at 5:30 p.m. ET in New York City. The event will be webcast live, and an archived version will be available for 30 days post-event. Nurix is a clinical-stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases. The announcement highlights the company's continued efforts to engage with the medical and financial communities.